Diagnostics Solutions Consultant
ZoetisFull Time
Mid-level (3 to 4 years), Senior (5 to 8 years)
Candidates must possess an integrated MolDx/SaaS solution using Tempus’s sequencing technology, comfort selling at the executive level, and a keen understanding of the payor and reimbursement environment in oncology and diagnostics. Strong understanding of molecular diagnostics for oncology, excellent knowledge of oncology, hematology, chemotherapeutics, and targeted agents, along with superior listening and problem-solving skills are required. Proficiency with Microsoft Office, particularly Excel and PowerPoint, and effective utilization of Salesforce.com are essential. Advanced presentation skills, business acumen, advanced written and oral communication skills, and strong administrative skills are also necessary. Frequent travel (>50%) throughout the territory is required.
The Clinical Account Executive will drive strategic business expansion and collaboration opportunities with major U.S. cancer centers, clinics, KOLs, and AMCs. They will structure strategic plans for client acquisition and retention, maximize client-bill contracting, and implement laboratory services agreements. Responsibilities include collaborating with sales positions to achieve company goals, identifying partnering opportunities, promoting web-based molecular information tools, and analyzing the competitive landscape. The role involves monitoring sales performance, developing a comprehensive business plan for the territory, and working effectively with individuals across multiple departments. Embracing and representing the Tempus company culture is also a key responsibility.
AI-driven healthcare data analysis platform
Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data to provide insights for physicians, helping them make better treatment decisions. This platform also aids pharmaceutical and biotech companies in drug development by identifying new targets and assessing treatment effectiveness. For patients, Tempus identifies personalized therapy options, particularly in cancer care, where their research has shown increased opportunities for tailored treatments. They have developed a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Tempus generates revenue by charging healthcare providers and companies for access to their platform and insights, setting them apart from competitors by their focus on personalized medicine and extensive cancer research.